Bookmark and Share
Pentostatin (CID 439693) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(14)
 
 
Inactive(67)
 
 
Inconclusive(2)
 
 
Unspecified(30)
 
 
Top Targets:
NR LBD AR(7)
 
 
NR LBD ER(7)
 
 
NR LBD GR(4)
 
 
NR LBD TR(3)
 
 
7TM GPCR Srsx(2)
 
 
BioAssay Types:
Confirmatory(53)
 
 
 
Literature(41)
 
 
 
 
Summary(15)
 
 
 
Screening(2)
 
 
BioActivity Types:
Potency(66)
 
 
 
Ki(8)
 
 
IC50(2)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 113    Data Row: 113   Total Pages: 3   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103589743]
Ki 1e-07Inhibition of adenosine deaminase [AID717435, Type: Literature]
View
2
[SID103589743]
Ki 1e-06Binding affinity towards calf spleen adenosine deaminase was determined [AID33661, Type: Literature]
View
3
[SID103589743]
Ki 1e-06Compound was tested for the inhibition of adenosine deaminase from calf intestine; Range of 0.01-0.001 nM [AID33670, Type: Literature]
View
4
[SID103589743]
Ki 2.5e-06Binding affinity (Ki) at calf intestinal adenosine deaminase. [AID33656, Type: Literature]
View
5
[SID103589743]
Ki 2.5e-06The compound was tested in vitro for inhibition of human erythrocytic adenosine deaminase. [AID33969, Type: Literature]
View
6
[SID103589743]
Ki 1e-05Binding affinity against Adenosine deaminase from calf intestinal mucosa was determined [AID33660, Type: Literature]
View
7
[SID103589743]
Ki 3.3e-05Inhibition constant against human adenosine deaminase was determined [AID33849, Type: Literature]
View
8
[SID103589743]
Ki 0.0001Compound was evaluated for the inhibition of adenosine deaminase [AID33846, Type: Literature]
View
9
[SID103589743]
IC50 0.25Compound was evaluated for the cytotoxicity against L1210 cells in presence of coformycin [AID98361, Type: Literature]
View
10
[SID103589743]
IC50 1.9Compound was evaluated for the cytotoxicity against L1210 cells in absence of coformycin [AID98360, Type: Literature]
View
11
[SID48416395]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
12
[SID144206967]
qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
13
[SID144206967]
qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]D(3) dopamine receptor isoform e [Homo sapiens] [gi:89191863]
View
14
[SID103589743]
Adenosine deaminase inhibitor [AID742835, Type: other]Adenosine deaminase [gi:113339]
View
15
[SID103589743]
Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice [AID8593, Type: Literature]
View
16
[SID103589743]
Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice [AID9760, Type: Literature]
View
17
[SID103589743]
Binding affinity against calf intestine adenosine deaminase enzyme; 10E-11 to 10e-12 M [AID33658, Type: Literature]
View
18
[SID103589743]
Relative enzyme affinity for adenosine deaminase was determined; No data [AID33829, Type: Literature]
View
19
[SID103589743]
Antitumor activity after administration (i.p.) in mice U937 cells at a dose of 0.025 mg/kg [AID116408, Type: Literature]
View
20
[SID103589743]
Antitumor activity after administration (p.o.) in mice U937 cells at a dose of 0.25 mg/kg [AID116409, Type: Literature]
View
21
[SID103589743]
Antitumor activity after administration (p.o.) in mice U937 cells at a dose of 2.5 mg/kg [AID116411, Type: Literature]
View
22
[SID103589743]
Antitumor activity (2.5, i.p.) on lymphoma U-937 tumor growth inoculated in mice [AID245704, Type: Literature]
View
23
[SID103589743]
Antitumor activity (0.25 mg/kg, i.p.) on lymphoma U-937 tumor growth inoculated in mice [AID245705, Type: Literature]
View
24
[SID103589743]
Octanol-water partition coefficient, log P of the compound [AID477295, Type: Literature]
View
25
[SID103589743]
FDA HLAED, liver enzyme composite activity [AID588214, Type: Literature]
View
26
[SID103589743]
FDA HLAED, alkaline phosphatase increase [AID588215, Type: Literature]
View
27
[SID103589743]
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase [AID588216, Type: Literature]
View
28
[SID103589743]
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase [AID588217, Type: Literature]
View
29
[SID103589743]
FDA HLAED, lactate dehydrogenase (LDH) increase [AID588218, Type: Literature]
View
30
[SID103589743]
FDA HLAED, gamma-glutamyl transferase (GGT) increase [AID588219, Type: Literature]
View
31
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia [AID625279, Type: Literature]
View
32
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis [AID625280, Type: Literature]
View
33
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis [AID625281, Type: Literature]
View
34
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis [AID625282, Type: Literature]
View
35
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests [AID625283, Type: Literature]
View
36
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure [AID625284, Type: Literature]
View
37
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis [AID625285, Type: Literature]
View
38
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis [AID625286, Type: Literature]
View
39
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly [AID625287, Type: Literature]
View
40
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice [AID625288, Type: Literature]
View
41
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease [AID625289, Type: Literature]
View
42
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty [AID625290, Type: Literature]
View
43
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal [AID625291, Type: Literature]
View
44
[SID103589743]
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score [AID625292, Type: Literature]
View
45
[SID144206967]
Potency-Replicate_1 qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability [AID651633, Type: confirmatory]
View
46
[SID144206967]
Potency-Replicate_1 qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability [AID651634, Type: confirmatory]
View
47
[SID144206967]
Potency qHTS for Inhibitors of binding or entry into cells for Lassa Virus [AID720533, Type: confirmatory]
View
48
[SID144206967]
Potency-Replicate_1 qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability [AID720634, Type: confirmatory]
View
49
[SID144206967]
Potency-Replicate_1 qHTS assay to identify aromatase inhibitors [AID743083, Type: confirmatory]cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens] [gi:119597822]
View
50
[SID144206967]
qHTS assay to identify aromatase inhibitors: Summary [AID743139, Type: summary]cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens] [gi:119597822]
View